Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.31 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4042670 | 0.92 | TSHR (0.38) | TSHRALDH1A1DNM1KCNH2FAAH | |
| SCHEMBL4140633 | 0.91 | TSHR (0.44) | TSHRALDH1A1DNM1KCNH2FAAH | |
| SCHEMBL6159782 | 0.89 | TSHR (0.48) | TSHRALDH1A1DNM1KCNH2FAAH | |
| SCHEMBL22157437 | 0.89 | TSHR (0.42) | TSHRALDH1A1DNM1KCNH2FAAH | |
| SCHEMBL28760238 | 0.89 | TSHR (0.48) | TSHRALDH1A1DNM1KCNH2FAAH | |
| SCHEMBL11233672 | 0.89 | TSHR (0.48) | TSHRALDH1A1DNM1KCNH2FAAH | |
| Hydrochloric Acid SCHEMBL22771836 | 0.89 | TSHR (0.42) | TSHRALDH1A1DNM1KCNH2FAAH | |
| SCHEMBL22157373 | 0.89 | TSHR (0.48) | TSHRALDH1A1DNM1KCNH2FAAH | |
| SCHEMBL8423278 | 0.89 | TSHR (0.48) | TSHRALDH1A1DNM1KCNH2FAAH | |
| SCHEMBL8421983 | 0.89 | TSHR (0.48) | TSHRALDH1A1DNM1KCNH2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6858608-B2 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | claimed |
| EP-1351957-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | Aventis Pharma S.A. (FR) | 2003-10-15 | — | — | EP | claimed |
| US-20030078263-A1 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA SA (FR) | 2003-04-24 | — | — | US | claimed |
| US-20030013711-A1 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2003-01-16 | — | — | US | claimed |
| WO-2002068408-A1 | CHEMICAL DERIVATIVES AND THE USE THEREOF AS AN ANTI-ELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2002-09-06 | — | — | WO | claimed |
| WO-2002055515-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2002-07-18 | — | — | WO | claimed |
| US-7179816-B2 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2007-02-20 | — | — | US | disclosed |
| US-20050070575-A1 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2005-03-31 | — | — | US | disclosed |
| US-6858608-B2 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| EP-1351957-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | Aventis Pharma S.A. (FR) | 2003-10-15 | — | — | EP | disclosed |
| US-20030078263-A1 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA SA (FR) | 2003-04-24 | — | — | US | disclosed |
| US-20030013711-A1 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2003-01-16 | — | — | US | disclosed |
| WO-2002068408-A1 | CHEMICAL DERIVATIVES AND THE USE THEREOF AS AN ANTI-ELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002055515-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013711-A1 | Chemical derivatives and their application as antitelomerase agents | NTPCR, DPYD, NME1 | TSHR 3851/4885ALDH1A1 640/4885DNM1 2033/4885 |
| US-20030078263-A1 | Chemical derivatives and their application as antitelomerase agents | TERT, TERF2, DUT | TSHR 3003/4885ALDH1A1 854/4885DNM1 2190/4885 |
| US-20050070575-A1 | Chemical derivatives and their application as antitelomerase agents | TERT, TERF2, DUT | TSHR 3003/4885ALDH1A1 854/4885DNM1 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.